NuCana plc (NCNA)
NASDAQ: NCNA · Real-Time Price · USD
1.400
-0.080 (-5.41%)
At close: Mar 27, 2026, 4:00 PM EDT
1.390
-0.010 (-0.71%)
After-hours: Mar 27, 2026, 7:28 PM EDT
NuCana Employees
As of December 31, 2024, NuCana had 22 total employees, including 20 full-time and 2 part-time employees. The number of employees decreased by 6 or -21.43% compared to the previous year.
Employees
22
Change (1Y)
-6
Growth (1Y)
-21.43%
Revenue / Employee
n/a
Profits / Employee
-$1,795,730
Market Cap
5.83M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 22 | -6 | -21.43% | 20 | 2 |
| Dec 31, 2023 | 28 | -3 | -9.68% | 25 | 3 |
| Dec 31, 2022 | 31 | -2 | -6.06% | 28 | 3 |
| Dec 31, 2021 | 33 | 4 | 13.79% | 31 | 2 |
| Jun 30, 2021 | 28 | - | - | 28 | 0 |
| Dec 31, 2020 | 29 | -2 | -6.45% | 27 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cardio Diagnostics Holdings | 17 |
| BioRestorative Therapies | 11 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 9 |
| Akari Therapeutics, | 9 |
| Ernexa Therapeutics | 7 |
| Mustang Bio | 6 |
| Addex Therapeutics | 2 |
NCNA News
- 9 days ago - NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - NuCana Appoints Theresa Bruce as Chief Operating Officer - GlobeNewsWire
- 3 months ago - NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma - GlobeNewsWire
- 4 months ago - NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China - GlobeNewsWire
- 7 months ago - NuCana Compliant with All Nasdaq Continued Listing Criteria - GlobeNewsWire
- 7 months ago - NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025 - GlobeNewsWire
- 7 months ago - NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire